Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease

被引:12
|
作者
Akhiyat, Nadia [2 ]
Lasho, Terra [3 ]
Ganji, Morsaleh [2 ]
Toya, Takumi [2 ]
Shi, Chang-Xin [6 ]
Chen, Xianfeng [7 ,8 ]
Braggio, Esteban [6 ]
Ahmad, Ali [2 ]
Corban, Michel T. [2 ]
Stewart, Keith [4 ,6 ]
Fernandez, Jenna [3 ]
Xie, Zhuoer [3 ]
Finke, Christy [3 ]
Lerman, Lilach O. [5 ]
Patnaik, Mrinal M. [3 ]
Lerman, Amir [1 ,2 ]
机构
[1] Mayo Clin, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Med, Div Cardiol, Rochester, MN USA
[3] Mayo Clin, Dept Med, Div Hematol Oncol, Rochester, MN USA
[4] Mayo Clin, Ctr Individualized Med, Rochester, MN USA
[5] Mayo Clin, Dept Med, Div Nephrol & Hypertens, Rochester, MN USA
[6] Mayo Clin, Dept Med, Div Hematol, Phoenix, AZ USA
[7] Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ USA
[8] Mayo Clin, Ctr Individualized Med, Scottsdale, AZ USA
基金
美国国家卫生研究院;
关键词
biomarker; CHIP clonal hematopoiesis of indeterminate potential; coronary artery disease; CHRONIC INFLAMMATION; HEART-FAILURE; FLOW RESERVE; TET2; RISK; PREVALENCE; REGULATOR; TARGET;
D O I
10.1161/ATVBAHA.122.318928
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:Clonal hematopoiesis (CH) of indeterminate potential (CHIP) is a risk factor for cardiovascular disease. The relationship between CHIP and coronary microvascular dysfunction (CMD) is unknown. The current study examines the association between CHIP and CH with CMD and the potential relationships in risk for adverse cardiovascular outcomes. Methods:In this retrospective observational study, targeted next-generation sequencing was performed for 177 participants with no coronary artery disease who presented with chest pain and underwent routine coronary functional angiogram. Patients with somatic mutations in leukemia-associated driver genes in hematopoietic stem and progenitor cells were examined; CHIP was considered at a variant allele fraction >= 2%; CH was considered at a variant allele fraction >= 1%. CMD was defined as coronary flow reserve to intracoronary adenosine of <= 2. Major adverse cardiovascular events considered were myocardial infarction, coronary revascularization, or stroke. Results:A total of 177 participants were examined. Mean follow-up was 12 +/- 7 years. A total of 17 patients had CHIP and 28 had CH. Cases with CMD (n=19) were compared with controls with no CMD (n=158). Cases were 56 +/- 9 years, were 68% women, and had more CHIP (27%; P=0.028) and CH (42%; P=0.001) than controls. CMD was associated with independent risk for major adverse cardiovascular events (hazard ratio, 3.89 [95% CI, 1.21-12.56]; P=0.023), and 32% of this risk was mediated by CH. The risk mediated by CH was approximate to 0.5x as large as the direct effect of CMD on major adverse cardiovascular events. Conclusions:In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.
引用
收藏
页码:774 / 783
页数:10
相关论文
共 50 条
  • [1] Clonal Hematopoiesis of Indeterminate Potential is Associated With Atrial Fibrillation in Patients With Early Coronary Artery Disease
    Akhiyat, Nadia
    Lasho, Terra
    Ganji, Morsaleh
    Corban, Michel T.
    Ahmad, Ali
    Lerman, Lilach O.
    Patnaik, Mrinal
    Lerman, Amir
    CIRCULATION, 2022, 146
  • [2] Invasive Assessment of Coronary Artery Disease in Clonal Hematopoiesis of Indeterminate Potential
    Heimlich, J. Brett
    Raddatz, Michael A.
    Wells, John
    Vlasschaert, Caitlyn
    Olson, Sydney
    Threadcraft, Marcus
    Foster, Kristoff
    Boateng, Emmanuel
    Umbarger, Kelsey
    Su, Yan Ru
    Roden, Dan M.
    Barker, Colin M.
    Bick, Alexander G.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2024, 17 (04):
  • [3] Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease
    M d Mesbah Uddin
    Ngoc Quynh H. Nguyen
    Bing Yu
    Jennifer A. Brody
    Akhil Pampana
    Tetsushi Nakao
    Myriam Fornage
    Jan Bressler
    Nona Sotoodehnia
    Joshua S. Weinstock
    Michael C. Honigberg
    Daniel Nachun
    Romit Bhattacharya
    Gabriel K. Griffin
    Varuna Chander
    Richard A. Gibbs
    Jerome I. Rotter
    Chunyu Liu
    Andrea A. Baccarelli
    Daniel I. Chasman
    Eric A. Whitsel
    Douglas P. Kiel
    Joanne M. Murabito
    Eric Boerwinkle
    Benjamin L. Ebert
    Siddhartha Jaiswal
    James S. Floyd
    Alexander G. Bick
    Christie M. Ballantyne
    Bruce M. Psaty
    Pradeep Natarajan
    Karen N. Conneely
    Nature Communications, 13
  • [4] Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease
    Uddin, M. D. Mesbah
    Nguyen, Ngoc Quynh H.
    Yu, Bing
    Brody, Jennifer A.
    Pampana, Akhil
    Nakao, Tetsushi
    Fornage, Myriam
    Bressler, Jan
    Sotoodehnia, Nona
    Weinstock, Joshua S.
    Honigberg, Michael C.
    Nachun, Daniel
    Bhattacharya, Romit
    Griffin, Gabriel K.
    Chander, Varuna
    Gibbs, Richard A.
    Rotter, Jerome, I
    Liu, Chunyu
    Baccarelli, Andrea A.
    Chasman, Daniel, I
    Whitsel, Eric A.
    Kiel, Douglas P.
    Murabito, Joanne M.
    Boerwinkle, Eric
    Ebert, Benjamin L.
    Jaiswal, Siddhartha
    Floyd, James S.
    Bick, Alexander G.
    Ballantyne, Christie M.
    Psaty, Bruce M.
    Natarajan, Pradeep
    Conneely, Karen N.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [5] Clonal Hematopoiesis of Indeterminate Potential Increases Mortality Risk in Coronary Artery Disease
    Von Scheidt, Moritz
    Adkar, Shaunak
    Krefting, Johannes
    Hoermann, Gregor
    Meggendorfer, Manja
    Bauer, Sabine
    Pugach, Irina
    Friess, Christian
    Ma, Angela
    Hao, Ke
    Steigerwald, Sophia
    Kessler, Thorsten
    Mokry, Michal
    Bongiovanni, Dario
    Fleig, Julia
    Oldenbuettel, Lilith
    Chen, Zhifen
    Hecker, Judith S.
    Bassermann, Florian
    Maegdefessel, Lars
    Graw, Matthias
    Ruusalepp, Arno
    Hilgendorf, Ingo
    Leuschner, Florian
    Koenig, Wolfgang
    Cremer, Sebastian
    Leistner, David
    Dimmeler, Stefanie
    Zeiher, Andreas
    Braun, Christian
    Mitchell, Shaneice
    Jaiswal, Siddhartha
    Kovacic, Jason
    Mann, Matthias
    Kastrati, Adnan
    Haferlach, Claudia
    Haferlach, Torsten
    Leeper, Nick
    Bjorkegren, Johan
    Schunkert, Heribert
    CIRCULATION, 2024, 150
  • [6] Coronary Endothelial Dysfunction in Humans is Associated With Elevated Expression of Clonal Hematopoiesis of Indeterminate Potential
    Ganji, Morsaleh
    Lasho, Terra
    Toya, Takumi
    Ahmed, Ali
    Corban, Michel
    Lerman, Lilach O.
    Patnaik, Mrinal
    Lerman, Amir
    CIRCULATION, 2020, 142
  • [7] Clonal Hematopoiesis of Indeterminate Potential is Associated With Pro-Inflammatory Markers in Patients With Established Coronary Artery Disease
    Sinnadurai, Siamala
    Vazquez, Enrique
    Diez-Diez, Miriam
    Quintas, Ana
    Martinez, Jorge de la Barrera
    Kondraciuk, Marcin
    Sawicka-Smiarowska, Emilia
    Chlabicz, Malgorzata
    CIRCULATION, 2023, 148
  • [8] Proteomic Analyses Reveal Mechanistic Links Between Clonal Hematopoiesis of Indeterminate Potential and Coronary Artery Disease
    Yu, Zhi
    Yu, Bing
    Vromman, Amelie
    Nguyen, Quynh H.
    Khetarpal, Sumeet
    Honigberg, Michael
    Lin, Amy E.
    Katz, Daniel H.
    Tahir, Usman A.
    Weinstock, Joshua S.
    Jaiswal, Siddhartha
    Austin, Thomas
    Ramachandran, Vasan S.
    Peloso, Gina
    Manson, Joann E.
    Haring, Bernhard
    Kooperberg, Charles
    Reiner, Alex P.
    Bis, Joshua
    Psaty, Bruce M.
    Correa, Adolfo
    Lange, Leslie
    Post, Wendy S.
    CIRCULATION, 2022, 146
  • [9] Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease
    Sara, Jaskanwal D.
    Widmer, R. Jay
    Matsuzawa, Yasushi
    Lennon, Ryan J.
    Lerman, Lilach O.
    Lerman, Amir
    JACC-CARDIOVASCULAR INTERVENTIONS, 2015, 8 (11) : 1445 - 1453
  • [10] CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL IN PERIPHERAL ARTERY DISEASE
    Buettner, P.
    Boettner, J.
    Krohn, K.
    Baber, R.
    Platzbecker, U.
    Cross, M.
    Thiele, H.
    Branzan, D.
    ATHEROSCLEROSIS, 2022, 355 : E33 - E34